Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma
Go back to Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma| (NASDAQ: KYMR) | Delayed: 98.25 -1.2 (1.21%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $99.45 | 52 Week High | $ | |||
| Open | $97.77 | 52 Week Low | $ | |||
| Day High | $100.69 | P/E | N/A | |||
| Day Low | $94.62 | EPS | $ | |||
| Volume | 1,368,159 | |||||
